Tolerating subretinal fluid in the treatment of neovascular age-related macular degeneration with intravitreal aflibercept

Objective: To compare the anatomical and functional outcomes of intensive and relaxed intravitreal aflibercept regimen in the management of neovascular age-related macular degeneration. Methods: The medical records of 50 eyes of 50 patients with treatment-naive neovascular age-related macular degene...

Full description

Bibliographic Details
Main Authors: Dilan Yildiz, Akin Cakir, Burak Erden, Selim Bolukbasi, Serkan Erdenöz, Mustafa Nuri Elcioglu
Format: Article
Language:English
Published: SAGE Publishing 2021-06-01
Series:Therapeutic Advances in Ophthalmology
Online Access:https://doi.org/10.1177/25158414211022874
Description
Summary:Objective: To compare the anatomical and functional outcomes of intensive and relaxed intravitreal aflibercept regimen in the management of neovascular age-related macular degeneration. Methods: The medical records of 50 eyes of 50 patients with treatment-naive neovascular age-related macular degeneration, who underwent intravitreal aflibercept therapy in the Retinal Department of University of Health Sciences Okmeydanı Training and Research Hospital (Istanbul, Turkey), were retrospectively reviewed. The demographic features and best-corrected visual acuities at baseline and at 1st-, 2nd-, 3rd-, 4th-, 6th-, 10th- and 12th- months, optical coherence tomography measurements, presence of intraretinal fluid, subretinal fluid and intraocular pressure values were studied. The patients were divided into two groups: intensive (subretinal fluid intolerant) and relaxed (<200 microns subretinal fluid tolerated) intravitreal aflibercept regimens. Results: The change in the mean best-corrected visual acuities from baseline to 12th month was 13.72 ± 33.97 letters in the intensive treatment group and 8.68 ± 27.22 in the relaxed group. There was no statistically significant difference between the groups ( p  = 0.566). Similar proportions of both groups achieved ⩾10 letters gain (%48 vs. %40, respectively; p  = 0.755) and ⩾10 letters loss (%20 vs. %24, respectively; p  = 0.755). The mean central subfield thickness values decreased statistically significantly in both groups ( p  < 0.001). There was no statistically significant difference between the groups (442.40 ± 161.32 to 318.0 ± 63.10 vs. 431.64 ± 151.52 to 303.08 ± 140.91, respectively; p  = 0.724). The mean total injection numbers were significantly lower in the relaxed group (6.4 ± 1.65 vs. 4.8 ± 1.45, respectively; p  = 0.01). Conclusion: Relaxed intravitreal aflibercept regimen has comparable efficiency and safety outcomes at 12 months with intensive intravitreal aflibercept regimen with fewer injections in the management of neovascular age-related macular degeneration.
ISSN:2515-8414